Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
News and updates for Travere Therapeutics, Inc. (TVTX) center on its work as a biopharmaceutical company focused on rare kidney, liver and metabolic diseases. Company announcements frequently highlight progress with FILSPARI (sparsentan), an oral, non-immunosuppressive therapy approved to slow kidney function decline in adults with primary IgA nephropathy (IgAN), and under supplemental FDA review as a potential treatment for focal segmental glomerulosclerosis (FSGS).
Investors following TVTX news can track regulatory milestones such as FDA review timelines, PDUFA target action dates and review extensions for the FILSPARI sNDA in FSGS. Travere also reports new clinical data from the Phase 3 DUPLEX and Phase 2 DUET studies in FSGS, as well as from PROTECT, SPARTAN and real-world analyses in IgAN. These updates often focus on proteinuria reduction, kidney function outcomes and correlations between biomarker changes and long-term kidney failure risk.
Travere’s news flow includes financial results and preliminary revenue updates, typically furnished via press releases and Form 8‑K filings, along with commentary on commercial performance of FILSPARI in IgAN. The company also issues releases on pipeline developments, including the planned restart of the pivotal Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria (HCU) and long-term metabolite reduction data from the COMPOSE study.
Additional news items cover partnership activities with CSL Vifor and Renalys Pharma, anticipated regional filings and launches, and Travere’s participation in major medical and investor conferences such as the American Society of Nephrology Kidney Week and large healthcare investment meetings. This page aggregates these developments so readers can follow how clinical, regulatory, commercial and partnership events may shape the company’s rare disease portfolio over time.
Travere Therapeutics (Nasdaq: TVTX) announced plans to offer $150 million in common stock through an underwritten public offering. This offering includes a 30-day option for underwriters to buy an additional 15% of shares. The offering is subject to market conditions, and the actual terms remain uncertain. BofA Securities, Jefferies, and SVB Leerink serve as joint book-running managers. The shares will be sold under a previously filed shelf registration statement effective since September 4, 2018.
Travere Therapeutics (NASDAQ: TVTX) announced that the FDA has granted Orphan Drug Designation for sparsentan to treat IgA nephropathy, a rare kidney disorder. This designation supports the development of sparsentan, which is currently in Phase 3 trials, aimed at addressing the unmet medical needs of IgAN patients. The Company anticipates topline data from interim assessments in 2021. Orphan Drug Designation enhances incentives for clinical trials and may provide seven years of market exclusivity if approved.
Travere Therapeutics (NASDAQ: TVTX) expects net product sales of approximately $51 million for Q4 2020 and $199 million for the fiscal year. The company aims to deliver first-in-class treatments for rare kidney diseases. Pivotal studies for sparsentan are on track for interim results in 2021, potentially supporting regulatory submissions. The DUPLEX study results are anticipated in February, followed by the PROTECT study in Q3. Travere expects to announce complete financial results for 2020 in late February.
Travere Therapeutics will host a virtual R&D Day on December 9, 2020, at 12:00 p.m. ET, to discuss key pipeline programs. The event will feature presentations from external experts and Travere’s senior management team, including Eric Dube, CEO, and Noah Rosenberg, CMO. Interested participants can access the live webcast on Travere's website in the 'Events & Presentations' section. A replay will be available for up to 60 days.
Travere is committed to developing therapies for patients with rare diseases.